Neurosense Therapeutics is trading 12.04% down now at $0.35 after investors continued reacting to disclosed delays in securing financing for the Phase 3 PARAGON ALS study.
- The company is pursuing alternatives to address Nasdaq’s minimum-bid requirement, including potential reverse-split authorization.
- No new August 20, 2026 company-specific announcement was confirmed; broader biotech weakness and declining major indices are adding pressure.